SLC5A2 and hydrops fetalis: SGLT2 inhibitors including dapagliflozin, empagliflozin, and sotagliflozin have been historically used in the treatment of type 2 diabetes, but emerging clinical evidence also shows that they also provide significant cardiovascular benefits in patients with HF.